These results led to several clinical trials using CAR-expressing NK-92 cells for patients with CD33+ AML (acute myeloid leukemia, ClinicalTrials.gov Identifier: NCT02944162), CD19+ (ClinicalTrials.gov Identifier: NCT02892695) or CD7+ (ClinicalTrials.gov Identifier: NCT02742727) leukemia/lymphoma and Her2+ glioblastoma (ClinicalTrials.gov Identifier: NCT03383978). This evidence concerns the gene ERBB2 and lymphoma.